Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies

Introduction Adalimumab is a fully humanized anti TNF a antibody that has showed its efficacy in Crohn's disease (CD) adult patients Its less immunogenic composition seems to be an advantage compared to previous anti TNF alpha, mainly infliximab Good response to adalimumab has been reported in...

Descripción completa

Detalles Bibliográficos
Autores: Martín de Carpi J, Pociello N, Varea V
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2010
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p1656
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1656
Access Level:acceso abierto
Palabra clave:Adalimumab
Anti TNF alpha
Paediatric Crohn s disease
Children
id ES_2b559c43cbef8bddfc312e52f36a8da1
oai_identifier_str oai:fsjd.fundanetsuite.com:p1656
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapiesMartín de Carpi JPociello NVarea VAdalimumabAnti TNF alphaPaediatric Crohn s diseaseChildrenIntroduction Adalimumab is a fully humanized anti TNF a antibody that has showed its efficacy in Crohn's disease (CD) adult patients Its less immunogenic composition seems to be an advantage compared to previous anti TNF alpha, mainly infliximab Good response to adalimumab has been reported in patients naive to infliximab, in those in whom infliximab has shown no efficacy and in those intolerant or who have lost previous response to it Adalimumab has shown also its efficacy as a second line anti TNF alpha in small series of paediatric CD but data regarding its use in children naive to infliximab are scarce Aim To report our experience with adalimumab as first line anti TNF alpha treatment in paediatric CD Patients and methods Four CD paediatric patients (2 boys) previously naive to infliximab have received adalimumab Mean age at diagnosis 13 years, 4 months Adalimumab was initiated in our patients soon after diagnosis (mean time from diagnosis 8 5 months, range 1 month 15days-14 months) at decreasing loading doses (160mg and 80mg two weeks after) and then 40 mg subsequently every two weeks Results The four patients entered in remission after the first dose of adalimumab (mean previous PCDAI 35, mean PCDAI after first dose 3 6) No adverse effects were registered Azathioprine was stopped after 4 months of combination therapy, without loss of efficacy or adverse reactions attributable to immunogenicity All the 4 patients have remained in remission on adalimumab monotherapy for a mean follow up of 17 months (range 9-20 months) Conclusion Adalimumab has shown its efficacy in our paediatric CD patients naive to other anti TNF alpha drugs Early introduction of anti TNF alpha antibodies in these patients could help to a better control of the disease Its less immunogenicity and the possibility of a home based administration are advantages when compared to other parenteral anti TNF treatments Change to monotherapy after prior successful combination therapy with azathioprine and adalimumab is a safe strategy that can help to minimize possible risks of intensive immunomodulation (C) 2010 European Crohn s and Colitis Organisation Published by Elsevier B V All rights reservedOXFORD UNIV PRESS2010info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1656Journal of Crohns & ColitisISSN: 18739946ISSNe: 18764479reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p16562026-05-27T12:37:41Z
dc.title.none.fl_str_mv Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
title Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
spellingShingle Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
Martín de Carpi J
Adalimumab
Anti TNF alpha
Paediatric Crohn s disease
Children
title_short Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
title_full Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
title_fullStr Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
title_full_unstemmed Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
title_sort Long-term efficacy of adalimumab in Paediatric Crohn's disease patients naive to other anti-TNF therapies
dc.creator.none.fl_str_mv Martín de Carpi J
Pociello N
Varea V
author Martín de Carpi J
author_facet Martín de Carpi J
Pociello N
Varea V
author_role author
author2 Pociello N
Varea V
author2_role author
author
dc.subject.none.fl_str_mv Adalimumab
Anti TNF alpha
Paediatric Crohn s disease
Children
topic Adalimumab
Anti TNF alpha
Paediatric Crohn s disease
Children
description Introduction Adalimumab is a fully humanized anti TNF a antibody that has showed its efficacy in Crohn's disease (CD) adult patients Its less immunogenic composition seems to be an advantage compared to previous anti TNF alpha, mainly infliximab Good response to adalimumab has been reported in patients naive to infliximab, in those in whom infliximab has shown no efficacy and in those intolerant or who have lost previous response to it Adalimumab has shown also its efficacy as a second line anti TNF alpha in small series of paediatric CD but data regarding its use in children naive to infliximab are scarce Aim To report our experience with adalimumab as first line anti TNF alpha treatment in paediatric CD Patients and methods Four CD paediatric patients (2 boys) previously naive to infliximab have received adalimumab Mean age at diagnosis 13 years, 4 months Adalimumab was initiated in our patients soon after diagnosis (mean time from diagnosis 8 5 months, range 1 month 15days-14 months) at decreasing loading doses (160mg and 80mg two weeks after) and then 40 mg subsequently every two weeks Results The four patients entered in remission after the first dose of adalimumab (mean previous PCDAI 35, mean PCDAI after first dose 3 6) No adverse effects were registered Azathioprine was stopped after 4 months of combination therapy, without loss of efficacy or adverse reactions attributable to immunogenicity All the 4 patients have remained in remission on adalimumab monotherapy for a mean follow up of 17 months (range 9-20 months) Conclusion Adalimumab has shown its efficacy in our paediatric CD patients naive to other anti TNF alpha drugs Early introduction of anti TNF alpha antibodies in these patients could help to a better control of the disease Its less immunogenicity and the possibility of a home based administration are advantages when compared to other parenteral anti TNF treatments Change to monotherapy after prior successful combination therapy with azathioprine and adalimumab is a safe strategy that can help to minimize possible risks of intensive immunomodulation (C) 2010 European Crohn s and Colitis Organisation Published by Elsevier B V All rights reserved
publishDate 2010
dc.date.none.fl_str_mv 2010
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1656
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1656
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv OXFORD UNIV PRESS
publisher.none.fl_str_mv OXFORD UNIV PRESS
dc.source.none.fl_str_mv Journal of Crohns & Colitis
ISSN: 18739946
ISSNe: 18764479
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405137878908928
score 15.81155

Similares en LA Referencia